# Geron Returns to Quarterly Profit as Rytelo Drives Q3 Revenue Growth By John Kim Canonical URL: https://www.tokenpost.com/news/business/49047 Published: 2026-11-05T05:02:37.000Z Updated: 2026-11-05T05:02:37.000Z Section: Business > Rytelo revenue growth helped reverse a run of quarterly losses. Shares rose more than 10% in early premarket trading Nov. 4. Geron Corporation posted a quarterly profit in Q3 2026 as revenue growth from its blood cancer drug Rytelo helped reverse a run of quarterly losses. Shares gained more than 10% in early premarket trading Wednesday, Nov. 4. Geron markets imetelstat as Rytelo. The results followed the company’s plan to end a late-stage study of the drug after efficacy concerns. Geron shares fell more than 20% on Oct. 28. The company’s plan to [stop the late-stage study]() followed concerns about the drug’s efficacy. ## Links in this article - [stop the late-stage study](https://www.tokenpost.com/news/business/42891)